Michael Kelly

Chief Scientific Officer

CureDuchenne

Dr. Michael Kelly is Chief Scientific Officer of CureDuchenne. Dr. Kelly, a senior pharmaceutical executive, brings more than 25 years of experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.

Before joining CureDuchenne, Dr. Kelly served as president and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline), among others.

Dr. Kelly holds a Ph.D. from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.

Disclosure statement:

Dr. Michael G. Kelly is president and CEO of MyoTherix Inc, a privately funded biopharmaceutical company focused on developing new therapies for rare diseases. Dr. Kelly is also the Chief Scientific Advisor to CureDuchenne, CureDuchenne Ventures and Synterys Inc.

Dr. Kelly is a senior pharmaceutical executive and brings more than 30 years of experience in drug discovery and development; he has previously served as president and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline), among others.